advertisement
Abstract #18526 Published in IGR 3-3
Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy
Tatton WG; Chalmers-Redman RME; Tatton NAEuropean Journal of Ophthalmology 2001; 11: Suppl 2 S12-S22
PURPOSE: Recent studies in the post-mortem human retina have suggested that apoptosis contributes to retinal ganglion cell (RGC) loss in glaucoma. If apoptosis contributes significantly to glaucomatous RGC loss, and if the specific apoptosis signalling pathways for glaucomatous apoptosis can be determined, agents that interrupt or oppose the signalling have the potential to slow the progression of glaucoma. METHODS: Recent data in animal models indicate that mitochondrially-dependent apoptosis contributes to RGC loss in glaucoma. Mitochondrially-dependent apoptosis involves proteins like BAX that increase mitochondrial membrane permeability and promote apoptosis and proteins like BCL-2 that decrease mitochondrial membrane permeability and reduce apoptosis. New protein synthesis induced by the alpha-2 agonist, brimonidine, prevents decreases in the levels of BCL-2 and thereby reduces mitochondrially-dependent apoptosis. CONCLUSIONS: Brimonidine appears to maintain BCL-2 levels by supporting the activity of an intrinsic anti-apoptosis signalling system that involves phosphorylation of protein kinase B. Phosphorylated protein kinase B appears to counteract the apoptosis signalling mechanisms which operate in glaucomatous retina.
Dr W.G. Tatton, Department of Neurology, Mount Sinai Medical Center, Annenberg 14-70, New York, NY 10029, USA. william.tatton@mssm.edu
Classification:
1.3 Pathogenesis (Part of: 1 General aspects)